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ABSTRACT 
Modeling Alzheimer’s Disease: A Statistical Approach to Understanding Pathogenesis Across 
Brain Regions  
 
 
Joshua Thomas Fuller 
Department of Psychology  
Texas A&M University 
 
Research Advisor: Dr. Steve Balsis  
Department of Psychology  
 
With a rapidly aging U.S. population, Alzheimer’s disease is a growing public health concern. 
Key to the success of future Alzheimer’s disease psychopharmacological clinical trials is 
understanding its complex pathogenesis with sophisticated statistical models. Presently, the 
literature has several models of Alzheimer’s disease pathogenesis that utilize fluctuations in 
biomarkers as the focal point of understanding progression across symptomatic states. Recent 
research has implicated regional volumetric changes in specific brain regions as one such 
biomarker of interest. However, the principal models are fundamentally theoretical, and these 
models are not derived purely from samples of clinical populations within a sophisticated 
statistical framework. Thus, these theoretical models are yet to be completely validated. 
Additionally, although some models have analyzed volumetric data from specific brain regions, 
no such model has assessed volumetric changes cross-regionally to document Alzheimer’s 
disease pathogenesis relative to healthy controls in a large, robust sample. 
 
This model analyzes the relationship among four crucial brain regions impacted by Alzheimer’s 
disease—the hippocampus, entorhinal cortex, fusiform gyrus, and the middle temporal gyrus—
using cross-sectional MRI data from a large study of Alzheimer’s disease patients and controls. 
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Results demonstrate a sequence through which we can understand where along the Alzheimer’s 
disease symptom spectrum each brain region becomes pathological relative to healthy controls. 
Understanding the neurodegenerative sequence of the hippocampus, entorhinal cortex, fusiform 
gyrus, and middle temporal gyrus is critical to our understanding of Alzheimer’s disease 
pathogenesis. Clinical implications include earlier and more accurate differential diagnosis, 
elucidation of disease subtypes, and future directions for pharmacological trials. 
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CHAPTER I  
INTRODUCTION AND BACKGROUND  
 
For a rapidly aging U.S. population, dementia is one of the greatest research and public health 
priorities. Alzheimer’s disease (AD) is the most prevalent form of dementia, affecting millions of 
relatively older U.S. citizens and tens of millions of people internationally (Alzheimer’s, 2015; 
Plassman et al., 2007; Rafii & Aisen, 2015). Cognitive decline due to AD is devastating and 
expensive, with an estimated $153 billion spent in 2015 on caring for AD and dementia patients 
(Alzheimer’s, 2015).  
 
As no cure for AD has been discovered, early and precise diagnosis is a key priority of research 
and clinical efforts. However, AD can only be confirmed with absolute certainty in a post-
mortem assessment of brain tissue in autopsy (Khachaturian, 1985, The Alzheimer’s Association 
Autopsy Network, n.d.). Various methods are used in differential diagnosis of AD, including 
neuropsychological assessments (e.g. the ADAS-cog, the MMSE, etc.) and Magnetic Resonance 
Imaging (MRI). These diagnostic tools are not perfect and are not universally available in 
different clinical settings, thus inspiring further research to refine these clinical tools with the 
aim of achieving an earlier and more precise diagnosis.  
 
Typically, AD usually affects different regions of the brain in a general sequence of 
neurodegeneration (Ray & Zhang, 2010). Results from previous in vivo and post-mortem 
neuroimaging research indicate that the disease initiates in the temporal lobe, affecting working 
memory and language (Fox, Crum, Scahill, Stevens, Janssen, & Rossor, 2001; Hardy, Mann, 
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Wester, & Winblad, 1986; Masdeau, Zubieta, & Arbizu, 2005). Eventually, it spreads toward the 
frontal lobe affecting control processes and logical thought. From there, the disease spreads 
across the parietal lobe and into the occipital lobe affecting basic perceptual processes (Wenk, 
2003). It then moves into the cerebellum, affecting balance. In its latest stage, AD reaches the 
brain stem, resulting in autonomic dysfunction such as difficulty breathing and arrhythmia (Lee, 
Ryan, Andreescu, Aizenstein, Lim, 2015). Although there is ample evidence of this general 
progression throughout these major divisions in the brain, less is known about the sequence of 
neurodegeneration across sub-regions of a single lobe. Specifically, degeneration within the 
temporal lobe has been the target of much inquiry recently as it is affected very early in the 
disease process (Masdeau, Zubieta, & Arbizu, 2005). 
 
Within the framework of current AD research effort is biomarker research emphasized on 
solidifying a verifiable AD pathogenesis model in the temporal lobe. Such a model would allow 
clinicians to understand the neuroanatomical and physiological processes associated with AD-
related cognitive decline. One area of biomarker research aims to assess correlations between 
volumetric changes in brain regions—specifically, the hippocampus, entorhinal cortex, fusiform 
gyrus, and middle temporal gyrus—during AD pathogenesis (see Biomarker Models Review). 
These four regions are presumed to be affected by AD because of the role they play in cognitive 
processes that deteriorate during AD-related decline (see Neuroanatomical Review).  
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Neuroanatomical review  
Hippocampus 
Located in the medial temporal lobe below the cerebral cortex, the hippocampus is the hallmark 
structure impacted in cognitive decline due to AD. In a review of ADNI papers, Weiner et al. 
(2012) note that “among the structures of the temporal lobe, hippocampal atrophy is the best 
studied structural biomarker, as it is one of the earliest structures to degenerate in AD.” 
Hippocampal atrophy due to AD is associated with general delayed memory recall (Convit et al., 
1997), as well as declines in episodic (Philippi et al., 2015; Rémy, Vayssière, Saint-Aubert, 
Barbeau, & Pariente, 2015) and spatial memory (Ezzati, Eslami, Lipton, Katz, Sliwinski, & 
Lipton, 2015).   
 
Entorhinal cortex  
Found in the medial temporal lobe, the entorhinal cortex serves as the primary interface of 
afferent information to the hippocampus from the neocortex. The entorhinal cortex receives 
projections from various cortical areas (Vadderah & Gould, 2016). The wide array of afferents 
that project to the hippocampus via the entorhinal cortex is what provides the repertoire of 
information that is available in declarative memories (e.g. remembering specific scents in 
episodic memory). 
 
Fusiform gyrus  
Located partially in the occipital and temporal lobes, the fusiform gyrus is separated from the 
limbic lobe by the collateral sulcus (Vadderah & Gold, 2016). Atrophy of the fusiform gyrus has 
been implicated in distinguishing the diagnostic categories of mild cognitive impairment (MCI ) 
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from AD (Convit et al., 1997). According to Vadderah & Gould (2016), the fusiform gyrus is 
implicated in language comprehension, higher order processing of visual information, and 
complex aspects of learning and memory. 
 
Middle temporal gyrus  
The precise function of the middle temporal gyrus is unknown. Research suggests that the 
middle temporal gyrus may be involved in a variety of higher cognitive processes, such as humor 
(Vandenberghe, Price, Wise, Josephs, & Frackowiak, 1996) and semantic processes such as  
“story-listening,” (Lehericy et al., 2000). 
 
Biomarker models review  
Current biomarker research aims to model AD pathogenesis with a focus on maximizing clinical 
utility of AD biomarker assessment (Bateman et al., 2012; Jack et al., 2010; Jack et al., 2013a). 
Among the research priorities of biomarker assessment is understanding the relationship between 
volumetric changes in brain regions during AD pathogenesis. Jack et al (2010) presents a 
“temporal model of AD biomarkers,” a model which postulated that AB amyloid protein 
deposition precedes hippocampal atrophy. While hailed as a hallmark of biomarker research, this 
“amyloid-cascade” hypothesis is constrained and theoretical, synthesizing data from existing 
biomarker into research into the model. Jack et al. (2013a) proposes a revision of this model that 
continues to implicate amyloid deposition as the foremost biomarker event in AD pathogenesis.  
 
While still hypothetical, other studies affirm Jack et al. (2013a)’s hypothesis, pointing to AB 
protein deposition as a preclinical biomarker of AD (Benzinger et al., 2013; Villemagne et al., 
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2013). Even though Benzinger et al. (2013) supports amyloid deposition as a forerunner of other 
AD biomarkers (e.g. neurofibrillary tangles), the conclusion that “volumetric and metabolic 
changes appear at approximately the same time in ADAD mutation carriers” actually challenges 
Jack et al. (2013a)’s AD biomarker model (Benzinger et al., 2013, E4506).   
Amyloid deposition is considered the hallmark of preclinical AD amongst many AD researchers 
and clinicians, and thus the amyloid-cascade hypothesis has been widely accepted. However, 
evidence exists that supports both “amyloid-first” and “neurodegeneration-first” biomarker 
models of AD-related cognitive decline (Jack et al., 2013b). While the amyloid-cascade 
hypothesis infers a specific sequence of related molecular biomarker events, the causes of a 
“neurodegeneration-first” sequence are unknown and add to the “controversy of disease 
pathogenesis,” (Jack et al., 2013b). 
 
Understanding the neurodegenerative process of the hippocampus, entorhinal cortex, fusiform 
gyrus, and middle temporal gyrus is essential to furthering our knowledge of AD pathogenesis. 
Presently, the majority of the literature proposes models that assess volumetric changes in merely 
one brain region at a time in an effort to correlate regional brain atrophy with results of clinical 
neuropsychological assessments (e.g. the MMSE and the ADAS-cog). I am unaware of any 
model has assessed volumetric changes cross-regionally during Alzheimer’s disease 
pathogenesis relative to healthy controls and intracranial volume. Additionally, the leading 
models are theoretical versus statistically derived from clinical samples, and therefore have not 
been validated. This study presents a statistically self-contained model of atrophy in 
neuroanatomical regions implicated in AD-related decline using a cross-section of MRI data 
from participants in the Alzheimer’s disease Neuroimaging Initiative (ADNI). 
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CHAPTER II 
METHODS 
 
ADNI measurement procedures 
Data used in the preparation of this article were obtained from the Alzheimer’s Disease 
Neuroimaging Initiative (ADNI) database, adni.loni.usc.edu. The ADNI was launched in 2003 as 
a public-private partnership. The initial goal of ADNI was to recruit 800 participants but ADNI 
has been followed by two other initiatives, ADNI-GO and ADNI-2. To date these three protocols 
have recruited over 1500 adults, ages 55 to 90, to participate in the research, consisting of older 
people who are cognitively healthy, people with early or late MCI, and people with early AD. 
Demographic information and clinical data used for this study were downloaded from the ADNI 
data repository (adni.loni.usc.edu) on May 28, 2014. Data for the current analyses come from 
individuals who completed baseline assessments and had complete data for key cognitive and 
brain variables described below (n = 1056).   
 
Participants 
The analysis for the present study used baseline data from 1056 participants (470 female, 45%) 
enrolled across all three ADNI phases. Participants were an average of 72.87-years-old (SD = 
6.99), highly educated (M = 16.09, SD = 2.77 years), and the majority identified their race as 
White (n = 970, 92%). Other races represented include Black or African American (n = 52, 5%), 
Asian (n = 17, 2%), American Indian or Alaskan Native (n = 2, 0%), and Native Hawaiian or 
Other Pacific Islander (n = 2, 0%); 11 participants (1%) reported that they were more than one 
race, and 2 participants (0%) were unknown. Thirty-six participants reported their ethnicity as 
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Hispanic or Latino (3%); 1012 (96%) reported that they were not Hispanic or Latino, and 8 (1%) 
were unknown. 
 
Baseline diagnoses represented a range of cognitive impairment: 341 (32%) were cognitively 
normal, 560 (53%) had MCI, and 155 (15%) had presumed Alzheimer’s dementia. We included 
the cognitively normal (CN) participants so that we could model the disease from the continuum 
of normal aging to pathological aging. In the ADNI, CN participants served as the controls and 
showed no signs of MCI, or dementia. CN participants had normal cognition (defined as CDR = 
0, MMSE between 24-30, and WMS-R Logical Memory II subscale score above education-
adjusted cutoffs). MCI participants had a subjective memory concern and significant amnestic 
dysfunction (defined by CDR = 0.5 plus an abnormal score on the WMS-R Logical Memory II 
subscale). However, MCI participants had sufficiently preserved functional abilities and global 
cognition (MMSE score between 24-30), such that they did not meet criteria for AD. Participants 
were diagnosed with probable dementia of probable AD if they met National Institute of 
Neurological and Communicative Disorders and Stroke/Alzheimer’s Disease and Related 
Disorders Association (NINCDS/ADRDA) criteria (McKhann et al., 1984). At the time of the 
ADNI diagnosis, AD participants demonstrated deficits in their global cognition, abnormal 
memory functioning (based on scores on the WMS-R Logical Memory II subscale), and showed 
significant concerns with memory (reported by the participant, study partner, or clinician). 
Finally, participants were excluded if they had a history of significant neurologic disease or brain 
trauma (including multi-infarct dementia and subdural hematoma).  
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Measures  
We assessed four neuroanatomical regions. In the ADNI sample, participants were evaluated 
using structural MRI scans to assess cortical volume and neuropsychological tests to assess 
cognitive performance. The procedures used are readily available online (adni.loni.usc.edu). 
Here, we describe it briefly:   
 
Neuroanatomical volume 
Structural MRI scans enable volumetric measurements of neuroanatomical regions, which can 
indicate patterns of volumetric changes and brain atrophy associated with AD. We used 
neuroanatomical volume of four temporal lobe brain regions: entorhinal cortex, hippocampus, 
fusiform gyrus, and middle temporal gyrus. The MRI procedures in the ADNI protocol were 
rigorous. Jack et al. (2008) outlines the eleven specific MRI guidelines from the ADNI protocol. 
Through the consistency mandated by the ADNI protocol, error in the collection MRI data was 
minimized since the data “must be consistent across sites and over time,” (Jack et al., 2008). 
All values included in the dataset were in cubic millimeters. The range in the dataset for these 
four variables was determined, and then values were binned into five equal bins (0 through 4). 
These are the values that were parameterized later in our model.  
 
Cognitive function 
Neuropsychological measures of memory, language, visuospatial abilities, and executive 
function represent the breadth of cognitive decline that occurs in AD and are widely used in 
clinical research to assess cognitive dysfunction. We analyzed data from measures that capture 
each of these cognitive domains. To assess memory functioning, we used data from the delayed 
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recall add on test to the Alzheimer’s Disease Assessment Scale – Cognition (ADAS-Cog; Mohs, 
Rosen, & Davis, 1983; Rosen, Mohs, Davis, 1984) and ADAS-Cog word recognition (Rosen et 
al., 1984), Rey Auditory Verbal Learning Test (Rey, 1964) Learning, Immediate Recall, Delayed 
Recall, and Recognition indicators. Each measure was binned into up to five equal bins, then 
those bins were summed across tests, then the sum was binned across five equal bins (0 to 4) to 
represent our Memory domain. For Language, the same process was carried out for ADAS-Cog 
Naming (Rosen et al., 1984), Boston Naming Test (Kaplan, Goodglass, & Brand, 1983), and 
Category Fluency-Animals (adapted from the CERAD Verbal Fluency test; Morris, 1989). For 
Visuospatial, we used the same procedure for ADAS-Cog Constructional Praxis (Rosen et al., 
1984), Clock Drawing Test (Goodglass & Kaplan, 1983) Command and Copy. Finally, for 
Executive, we used ADAS-Cog Number Cancellation (Rosen et al., 1984), and Trail Making 
Test A and B (Reitan, 1958; Reitan & Wolfson, 1985). Additional cognitive measures used were 
the Mini Mental State Examination (Folstein & Folstein, 1975), and the CDR-SOB. 
 
Analyses 
The analyses used in this model were aimed at providing a statistical model of the Alzheimer’s 
cascade. This cascade cuts across multiple domains, and thus indicators of the domains have a 
sigmoid shaped relationship to the continuum of the disease (see Jack et al., 2013). Thus, to 
model the disease, we need statistical machinery that can identify a core defining dimension of 
the disease within one domain, then model the ability of the other domains to indicate this 
domain with sigmoid monotonically increasing function curves. Item response theory (IRT) 
provides us that machinery. IRT uses multiple markers to statistically define a single latent 
dimension (in this case, cognitive dysfunction in AD) and simultaneously determine the degree 
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to which individual markers are related to that dimension with sigmoidal curves (see Jack et al., 
2013). For this analysis, we defined the latent continuum in terms of brain volume across four 
key neuroanatomical regions implicated in AD (entorhinal cortex, hippocampus, fusiform gyrus, 
and middle temporal gyrus). Then, using IRT software (IRT-LR-DIF), we estimated the item 
parameters for each brain region. Then we used those items as “anchors” to define our latent 
continuum, and we determined the extent to which the following MRI biomarkers indicate that 
latent continuum: entorhinal cortex, hippocampus, fusiform gyrus, and middle temporal gyrus.  
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CHAPTER III 
RESULTS 
 
To assess if our four variables covaried adequately together to fulfill the requirements for an 
assumption of unidimensionality, an exploratory factor analysis (EFA) in SPSS was conducted to 
determine if the ratio of first to second eigenvalue was greater than the 3:1 ratio suggested by 
Embretson and Reise (2000). Results from the EFA indicated the data were indeed sufficiently 
unidimensional for IRT analyses. Our first eigenvalue was 2.21 and the second was .73, creating 
a ratio of 3.03. Figure 1 (Appendix A) illustrates the ratios of eigenvalues of the neurocognitive 
variables assessed in our statistical approach. 
 
Next, a confirmatory factor analysis (CFA) was additionally utilized to determine whether the 
data were unidimensional enough for IRT analyses. Hu and Bentler (1999) showed that 
hypothetical structural models are a relatively good fit to observed data when the Tucker-Lewis 
Index (TLI; Tucker & Lewis, 1973) and comparative fit index (CFI; Bentler, 1990) values are 
close to .95 and the root mean squared error of approximation (RMSEA; Steiger & Lind, 1980) 
is less than .06.  Using these recommended cutoffs, we concluded that the data (CFI = 0.996, TLI 
= 0.99, RMSEA = 0.04) were outstanding fits to the specified unidimensional model criteria.  A 
non-significant chi-square test was used to support further this determination. The Chi-Square 
test 4.94 (2), p > .05 was non-significant, providing further confirmation that the data were 
unidimensional enough for IRT analyses. Taken together, the analyses suggest our data are 
robustly unidimensional and suitable for the main analyses. 
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The data were analyzed following the EFA and CFA using the aforementioned IRT software 
(IRT-LR-DIF). Theta values for each regional brain volume were derived. These theta values 
were then used to generate four sigmoidal curves, representing the probability of relative 
volumetric deficits across the four brain regions of interest in this study. Figure 2 elucidates 
those curves (Appendix A). 
 
Figure 2 is a graphical representation of the probability of volumetric deficits as they vary across 
brain regions in relation to AD-related cognitive dysfunction. The distribution in curves across 
the latent continuum (θ) suggests that at lower levels of AD-related cognitive dysfunction, the 
fusiform gyrus reaches P = 0.50 of relative volumetric deficits (θ = -3.1). Accordingly, the 
entorhinal cortex reaches P = 0.50 of relative volumetric deficits at slightly higher levels of AD-
related cognitive dysfunction (θ = -1.52). Further, the hippocampus reaches P = 0.50 of relative 
volumetric deficits at slightly higher levels of AD-related cognitive dysfunction (θ = -0.97). 
Lastly, the middle temporal gyrus reaches P = 0.50 of relative volumetric deficits at slightly 
higher levels of AD-related cognitive dysfunction (θ = -0.58). 
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CHAPTER IV 
DISCUSSION 
 
The model presented in this thesis demonstrates a sequence of neurodegeneration in temporal 
lobe sub-regions observed in our AD patient cross-section. Our model aligns with previous 
research, demonstrating that volumetric deficits in the entorhinal cortex are seen at a relatively 
low level of disease severity. The entorhinal cortex is closely followed by those of the 
hippocampus and middle temporal gyrus (Du et al., 2004; Killiany et al., 2002). Interestingly, the 
fusiform gyrus is affected by tissue loss at a much lower level of disease severity than the other 
neuroanatomical structures in this study. The significant gap between the fusiform gyrus and the 
remaining three curves suggests that neurodegenration of the fusiform gyrus may possibly be an 
earlier indicator of pathology. Increased probability in statistically significant volumetric 
declines in the fusiform gyrus in our model appears at lower levels of cognitive dysfunction. The 
development of specific neuropsychological assessments geared towards measuring language 
and object recognition function associated with the action of the fusiform gyrus may be a 
promising area of research. While it is tempting to associate degeneration in specific brain 
regions with direct changes in cognition, it is important to recognize, however, that the 
relationship between the fusiform gyrus and cognitive outcomes, like all other brain regions with 
their respective functions, are associations and not necessarily casual. Our model suggests that 
structural changes in the fusiform gyrus may be correlated with subtle cognitive changes that 
occur earlier in the disease process. As this is a novel statistical model of changes in brain region 
volumes, further study of the fusiform gyrus is needed to validate this finding.  
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Limitations of this model must be addressed. First, the present model is cross-sectional versus 
longitudinal. Longitudinal modeling of disease severity is clinically relevant and of research 
interest, as Alzheimer’s disease is a progressive neurodegenerative disease that follows a general 
progression. However, cross-sectional modeling is a fruitful base for further research into precise 
statistical modeling. Second, only one dataset (ADNI) was analyzed in our work. However, this 
particular dataset is robust and very well characterized, replete with demographic, physiological, 
and cognitive data points. Additionally, the large sample size (n = 1056) mined from the ADNI 
database facilitates increases generalizability to clinical populations that are not captured by the 
database. ADNI is also an ethnically homogenous database; 8% of participants identified as non-
white (n = 86). Our analyses should be replicated to cross-validate the model in other more 
ethnically heterogeneous populations. Thirdly, our model does not consider volumetric changes 
in other possibly affected regions of the brain. Nevertheless, the four regions presented in this 
study are of clinical interest, as the literature suggests they relevant to cognitive and functional 
outcomes, especially in AD patients (O’Brien, 2014; Torisson et al, 2014). Lastly, replication of 
our model is needed, as this an initial attempt to elucidate the relationship between 
neuroanatomical volumes and cognitive dysfunction. Nevertheless, this model is mathematically 
derived and therefore a promising foundation for future replication studies. 
 
Future directions of investigation are numerous. Further research of the function and etiological 
significance of the fusiform gyrus is clearly necessary; to our knowledge, our model is the first 
of its kind to implicate the fusiform gyrus as an area of specific interest early on along the 
continuum of cognitive decline. Our findings suggest that neurodegenration of this brain region 
may reflect cognitive decline associated with Alzheimer’s disease earlier than currently verified 
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biomarkers. Additionally, studying other structural changes in different regions of the brain may 
offer insight into specific facets of etiology or pathology. The literature’s current understanding 
of the numerous and complex neuroanatomical structures and pathways in the brain is still 
considerably limited. There may be additional regions or structures that are relevant to AD 
pathogenesis and could therefore be added to the present model.  
 
As was mentioned previously, the represented model is cross-sectional in nature. This may be 
useful for comparisons of group characteristics, but less so at the individual level. Continued 
utilization of the ADNI and other databases may result in the replication of this model, followed 
by confirmatory longitudinal models that represent changes in brain region volumes and, 
accordingly, disease severity over time. Furthermore, both cross-sectional and longitudinal 
models may be further developed to include a third, highly pertinent dimension that reflects 
functional status. Such models will be more advanced and represent the multivariate nature of 
the disease, graphically measuring the correlations between neuroanatomical, cognitive, and 
functional changes.  
 
Statistical modeling of disease pathology is a powerful research tool that can be applied to 
various clinical problems. Although not mentioned previously in this thesis, our approach to 
modeling AD statistically can be extended to create similar statistical models that examine other 
hallmarks of AD pathology. For example, we are in the process of deriving an empirical model 
of neuropsychiatric symptoms (e.g., depression, hallucinations, anxiety) along the AD 
continuum. Neuropsychiatric symptoms due to AD or comorbid pathology (e.g., Schizophrenia) 
are common in AD patient populations (Lyketsos et al., 2011). It is possible that modeling these 
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non-cognitive biomarkers may provide a fresh perspective on the disease that would be clinically 
relevant and have high utility.  
 
21 
	  
REFERENCES 
 
Alzheimer’s Association. (2015). 2015 Alzheimer's disease facts and figures. Alzheimer's & 
dementia: the journal of the Alzheimer's Association, 11(3), 332. 
 
Alzheimer’s Association Autopsy Assistance Network. (n.d.). Questions and answers about 
autopsy. Seattle, WA: Alzheimer’s Association Central Western State Chapter.  
 
Bateman, R. J., Xiong, C., Benzinger, T. L., Fagan, A. M., Goate, A., Fox, N. C., ... & Morris, J. 
C. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease. 
New England  Journal of Medicine, 367(9), 795-804. 
 
Benzinger, T. L., Blazey, T., Jack, C. R., Koeppe, R. A., Su, Y., Xiong, C., ... & Morris, J. C. 
(2013). Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s 
disease. Proceedings of the National Academy of Sciences, 110(47), E4502-E4509. 
 
Convit, A., De Leon, M. J., Tarshish, C., De Santi, S., Tsui, W., Rusinek, H., & George, A. 
(1997). Specific hippocampal volume reductions in individuals at risk for Alzheimer’s 
disease. Neurobiology of Aging, 18(2), 131-138. 
 
Du, A. T., Schuff, N., Kramer, J. H., Ganzer, S., Zhu, X. P., Jagust, W. J., ... & Chui, H. C. 
(2004). Higher atrophy rate of entorhinal cortex than hippocampus in AD. Neurology,  
 62(3), 422-427. 
 
Embretson, S., Reise, S., & Reise, S. P. (2000). Item Response Theory for Psychologists. 
Lawrence Earlboum associates. Inc., NJ. 
 
Ezzati, A., Eslami, V., Lipton, M., Katz, M., Sliwinski, M., & Lipton, R. (2015). Verbal episodic 
memory and spatial memory correlate differentially with hippocampal volume in older 
adults. (P5. 019). Neurology, 84(14 Supplement), P5-019. 
 
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). “Mini-Mental State.” A practical 
method for grading the cognitive state of patients for the clinician. Journal of Psychiatric 
Research, 12, 189-198. 
 
22 
	  
Fox, N.C., Crum, W.R., Scahill, R.I., Stevens, J.M., Janssen, J.C., & Rossor, M.N. (2001). 
Imaging of onset and progression of Alzheimer’s disease with voxel-compression 
mapping of serial magnetic resonance images. The Lancet, 358(9277), 201-5. 
 
Goodglass, H., & Kaplan, E. (1983). The Assessment of Aphasia and Related Disorders. 
Philadelphia: Lea and Febiger. 
 
Hardy, J.A., Mann, D.M.A., Wester, P., & Winblad, B. (1986). An integrative hypothesis 
concerning the pathogenesis and progression of Alzheimer's disease. Neurobiology of 
Aging, 7(6), 489-502. 
 
Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., ... & 
Weiner, M. W. (2008). The Alzheimer's disease neuroimaging initiative (ADNI): MRI 
methods. Journal of Magnetic Resonance Imaging, 27(4), 685-691. 
 
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., ... & 
Trojanowski, J. Q. (2013a). Tracking pathophysiological processes in Alzheimer's 
disease: an updated hypothetical model of dynamic biomarkers. The Lancet Neurology, 
12(2), 207-216. 
 
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., ... & 
Trojanowski, J. Q. (2010). Hypothetical model of dynamic biomarkers of the Alzheimer's 
pathological cascade. The Lancet Neurology, 9(1), 119-128. 
 
Jack, C. R., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V., Vemuri, P., ... & Petersen, 
R. C. (2013b). Amyloid-first and neurodegeneration-first profiles characterize incident 
amyloid PET positivity. Neurology, 81(20), 1732-1740. 
 
Kaplan, E., Goodglass, H., & Brand, S. (1983). Boston naming test. Philadelphia: Lea & Febiger, 
1983. 
 
Khachaturian, Z. S. (1985). Diagnosis of Alzheimer's disease. Archives of Neurology, 42(11), 
1097-1105. 
 
Killiany, R. J., Hyman, B. T., Gomez-Isla, T. A., Moss, M. B., Kikinis, R., Jolesz, F., ... & 
Albert, M. S. (2002). MRI measures of entorhinal cortex vs hippocampus in preclinical 
AD. Neurology, 58(8), 1188-1196. 
23 
	  
Lee, J.H., Ryan, J., Andreescu, C., Aizenstein, H., & Lim, H.K. (2015). Brainstem 
morphological changes in Alzheimer’s disease. NeuroReport, 26(7), 411-5. 
 
Lehericy, S., Cohen, L., Bazin, B., Samson, S., Giacomini, E., Rougetet, R., ... & Baulac, M. 
(2000). Functional MR evaluation of temporal and frontal language dominance compared 
with the Wada test. Neurology, 54(8), 1625-1633. 
 
Lyketsos, C. G., Carrillo, M. C., Ryan, J. M., Khachaturian, A. S., Trzepacz, P., Amatniek, J., ... 
& Miller, D. S. (2011). Neuropsychiatric symptoms in Alzheimer’s disease. Alzheimer's 
& Dementia, 7(5), 532-539. 
 
Masdeau, J.C., Zubieta, J.L., & Arbizu, J. (2005). Neuroimaging as a marker of the onset and 
progression of Alzheimer's disease. Journal of the Neurological Sciences, 236(1-2), 55-
64. 
 
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). 
Clinical diagnosis of Alzheimer's disease Report of the NINCDS-­‐ADRDA Work Group* 
under the auspices of Department of Health and Human Services Task Force on 
Alzheimer's Disease. Neurology, 34(7), 939-939. 
 
Morris, J. C. (1992). The Clinical Dementia Rating (CDR): Current vision and scoring rules 
Neurology, 43, 2412-2414. 
 
O'brien, J. T. (2014). Role of imaging techniques in the diagnosis of dementia. The British 
journal of radiology. 
 
Philippi, N., Botzung, A., Noblet, V., Rousseau, F., Després, O., Cretin, B., ... & Manning, L. 
(2015). Impaired emotional autobiographical memory associated with right amygdalar-
hippocampal atrophy in Alzheimer’s disease patients. Frontiers in aging neuroscience, 7. 
 
Plassman, B.L., Langa, K.M., Fisher, G.G., Heeringa, S.G., Weir, D.R., Ofstedal, M.B…. 
Wallace, R.B. (2007). Prevalence of Dementia in the United States: The Aging, 
Demographics, and Memory Study. Neuroepidemiology, 29(1-2): 125-32. 
 
Rafii, M. S., & Aisen, P. S. (2015). Advances in Alzheimer’s Disease Drug Development. BMC 
medicine, 13(1), 62. 
24 
	  
Ray, M. & Zhang, W. (2010). Analysis of Alzheimer's disease severity across brain regions by 
topological analysis of gene co-expression networks. BMC Systems Biology, 4, 136. 
 
Reitan, R.M. (1958). Validity of the Trail Making Test as an indication of organic brain damage. 
Perceptual Motor Skills, 8, 271-276. 
 
Reitan, R., & Wolfson, D. (1985). The Halstead-Reitan Neuropsychological Test Battery. 
Tucson: Neuropsychology Press. 
 
Rey, A. (1964). L’examen Clinique en psychologie. Paris: Presses Universitaires de France. 
 
Rémy, F., Vayssière, N., Saint-Aubert, L., Barbeau, E., & Pariente, J. (2015). White matter 
disruption at the prodromal stage of Alzheimer's disease: Relationships with hippocampal 
atrophy and episodic memory performance. NeuroImage: Clinical, 7, 482-492. 
 
Rosen, W. G., Mohs, R. C., & Davis, K. L. (1984). A new rating scale for Alzheimer’s disease.  
American Journal of Psychiatry, 141, 1356-1364. 
 
Torisson, G., van Westen, D., Minthon, L., Stavenow, L., & Londos, E. (2014). Medial temporal 
lobe atrophy is frequent, underreported, and has important clinical correlates in medical 
inpatients. Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 10(4), 
P537. 
 
Vadderah, TW., & Gould, D. J. (2016). Notle’s the human brain: An Introduction to its 
Functional Anatomy. (7th ed.) Philadelphia, PA: Elsevier.  
 
Vandenberghe, R., Price, C., Wise, R., Josephs, O., & Frackowiak, R. S. (1996). Functional 
anatomy of a common semantic system for words and pictures. Nature, 383(6597), 254-
6. 
 
Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., ... & 
Masters, C. L. (2013). Amyloid β deposition, neurodegeneration, and cognitive decline in 
sporadic Alzheimer's disease: a prospective cohort study. The Lancet Neurology, 12(4), 
357-367. 
 
25 
	  
Weiner, M. W., Veitch, D. P., Aisen P. S., Beckett, L. A., Cairns N. J., Green R. C., ... & 
Alzheimer’s Disease Neuroimagining Initiative. (2012). The Alzheimer’s Disease 
Neuroimaging Initiative: A review of papers published since its inception. Alzheimer’s & 
Dementia, 8(1), S1-S68.  
 
Wenk, G.L. (2003). Neuropathologic changes in Alzheimer’s disease. The Journal of Clinical 
Psychiatry, 64(9), 7-10. 
 
26 
	  
APPENDIX A 
 
 
Figure 1. Scree plot of Neurocognitive Variables. This graph illustrates the ratios of eigenvalues 
of the neurocognitive variables assessed in our statistical approach. This Exploratory Factor 
Analysis (EFA) was the first step in validating that our AD dysfunction continuum was 
sufficiently unidimensional for further analyses.  
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Figure 2. Probability of Volumetric Deficits Varies across Brain Region and AD-Related 
Cognitive Dysfunction. This figure is a graphical representation of the probability of volumetric 
deficits as they vary across brain regions in relation to AD-related cognitive dysfunction. The 
distribution in curves across the latent continuum (θ) suggests that at lower levels of AD-related 
cognitive dysfunction, the fusiform gyrus reaches P = 0.50 of relative volumetric deficits (θ = -
3.1). Accordingly, the entorhinal cortex reaches P = 0.50 of relative volumetric deficits at 
slightly higher levels of AD-related cognitive dysfunction (θ = -1.52). Further, the hippocampus 
reaches P = 0.50 of relative volumetric deficits at slightly higher levels of AD-related cognitive 
dysfunction (θ = -0.97). Lastly, the middle temporal gyrus reaches P = 0.50 of relative 
volumetric deficits at slightly higher levels of AD-related cognitive dysfunction (θ = -0.58). 
